Search
Revefenacin
go.drugbank.com/drugs/DB11855ApprovedInvestigational[A40026] It was developed by Theravance Biopharma and FDA approved on November 9, 2018.[L4818]
Propacetamol
go.drugbank.com/drugs/DB09288Investigational[A7892] It is not available in the United States but this prodrug has been widely used in other countries such as France since 1985.[L1505]
Prothrombin
go.drugbank.com/drugs/DB11311ApprovedInvestigationalProthrombin Complex Concentrate (Human), is indicated for the urgent reversal of acquired coagulation factor deficiency induced by Vitamin K antagonist (VKA, e.g., warfarin) therapy in adult patients with
Methylene blue
go.drugbank.com/drugs/DB09241ApprovedInvestigationalHistorically, it has been widely used in Africa to treat malaria, but now it disappeared when chloroquine (CQ) and other drugs entered the market. … The intravenous form of methylene blue is approved by the FDA for the treatment of pediatric and adult patients with acquired methemoglobinemia.
Pilocarpine
go.drugbank.com/drugs/DB01085ApprovedInvestigationalThe usage of glaucoma by pilocarpine dates back to 1875.[A262041] … [A262016, A262036] Pilocarpine is associated with parasympathomimetic effects by selectively working on muscarinic receptors.
Dicloxacillin
go.drugbank.com/drugs/DB00485ApprovedInvestigationalVet approvedOne of the penicillins which is resistant to penicillinase.
Trastuzumab deruxtecan
go.drugbank.com/drugs/DB14962ApprovedInvestigational[A188988] Trastuzumab deruxtecan was developed by Daiichi Sankyo in collaboration with AstraZeneca and was first approved by the FDA in 2019.[L10842]
Angiotensin II
go.drugbank.com/drugs/DB11842ApprovedInvestigationalto one third of patients in the intensive care unit, the FDA determined that there is a need for treatment options for critically ill hypotensive patients who do not adequately respond to currently available
Carbamazepine
go.drugbank.com/drugs/DB00564ApprovedInvestigationalIt was initially approved by the FDA in 1965.[A180301] Aside from the above uses, this drug is also given to control the symptoms of bipolar 1.
Macimorelin
go.drugbank.com/drugs/DB13074ApprovedWhile there are various therapies available such as GH replacement therapy, the absence of panhypopituitarism and low serum IGF-I levels with nonspecific clinical symptoms pose challenges to the detection … Macimorelin, developed by Aeterna Zentaris, was approved by the FDA in December 2017 under the market name Macrilen for oral solution.